Home Overview Press Room Blog Publications For Students about us
Search

About Sequencing & Genomics


An organism's genome refers to all the hereditary information encoded in its genes. Sequencing a complete genome, a gene, or a fragment of genetic material involves determining the order of its sub-units: adenine, cytosine, guanine, and thymine.

Scientists are using individuals' genetic sequences to map and catalog human genetic variation in order to improve understanding of human biology, disease susceptibility, and drug response. As costs falls rapidly, the scale and speed of gene sequencing is increasing. The Human Genome Project required thirteen years and $3 billion to sequence the first complete, general human genome. Subsequent projects, such as the International HapMap Project, examined genetic variation between population groups, raising concerns of giving undue biological significance to social categories of race.

Now, the sequencing of complete genomes of specific individuals is becoming almost routine. For example, the Personal Genome Project plans to sequence 100,000 genomes.

Lower prices have also opened the door to companies that offer personal, direct-to-consumer genetic tests.


This scientist is trying to stop a lab-created global disasterby Kristen V. BrownFusionJune 27th, 2016Kevin Esvelt, one of the first scientists to realize CRISPR could be used in gene drives, calls himself a "critic of genetic engineering" and says, "If we misuse our power, we lose the trust. That is the tightrope we walk."
All about the base: New businesses eye the opportunities in managing genome dataThe EconomistJune 25th, 2016Currently, one firm - Illumina - controls 70% of a market worth $3.3 billion in 2015.
CRISPR Therapeutics adds $38M to Series B pot, but lags behind Parkerby Ben AdamsFierce BiotechJune 24th, 2016An NIH committee has backed a study funded by billionaire Sean Parker that will attempt to alter the T cells of 15 people with cancer.
Theyíre going to CRISPR people. What could possibly go wrong?by Sharon BegleySTATJune 23rd, 2016Possible consequences range from off-target alterations to conflicts of interest in the clinical trial.
Stem Cells: Where Science, Hope and Hype Meetby Danielle VentonKQED NewsJune 22nd, 2016California voters "were led to believe...that stem cell therapies were miraculous cures that were right around the corner...but that didnít really reflect scientific reality."
23andMe Sells Data for Drug Searchby Antonio RegaladoMIT Technology ReviewJune 21st, 201623andMe is monetizing DNA rather the way Facebook makes money from our "likes." Whatís more, it gets its customers to pay for the privilege.
Federal Oversight Group Has Complaints But Says Yes To CRISPR Trialby Alex LashXconomyJune 21st, 2016Despite worries about conflict of interest, an NIH committee voted to let researchers move ahead with a clinical trial that could be the first use of CRISPR-Cas9 in a human treatment.
Money Behind First CRISPR Test? Itís from Internet Billionaire Sean Parkerby Antonio RegaladoMIT Technology ReviewJune 20th, 2016Parkerís foundation is unusual because it says it will control patents on research it funds and even bring treatments to market.
First Human Test of CRISPR Proposedby Antonio RegaladoMIT Technology ReviewJune 16th, 2016The proposed cancer treatment is an immune therapy in which a patientís own blood cells will be removed and genetically altered.
How iPS cells changed the worldby Megan ScudellariNatureJune 15th, 2016Though therapies using induced pluripotent stem cells have proved challenging, iPS cells have become important for modelling and investigating human diseases, as well as for screening drugs.
Displaying 1-10 of 1321  
Next >> 
Last Page » 
« Show Complete List » 


ESPAÑOL | PORTUGUÊS | Русский

home | overview | blog | publications| about us | donate | newsletter | press room | privacy policy

CGS • 1122 University Ave, Suite 100, Berkeley, CA 94702 • • (p) 1.510.665.7760 • (F) 1.510.665.8760